Literature DB >> 17720878

Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells.

Ewa Grudzien-Nogalska1, Jacek Jemielity, Joanna Kowalska, Edward Darzynkiewicz, Robert E Rhoads.   

Abstract

Capped RNAs synthesized by in vitro transcription have found wide utility for studying mRNA function and metabolism and for producing proteins of interest. We characterize here a recently synthesized series of cap analogs with improved properties that contain a sulfur substitution for a nonbridging oxygen in either the alpha-, beta-, or gamma-phosphate moieties, m(2) (7,2'-O )Gppp(S)G, m(2) (7,2'-O )Gpp(S)pG, and m(2) (7,2'-O )Gp(S)ppG, respectively. The new compounds were also modified at the 2'-O position of the m(7)Guo to make them anti-reverse cap analogs (ARCAs), i.e., they are incorporated exclusively in the correct orientation during in vitro transcription. Each of the S-ARCAs exists in two diastereoisomeric forms (D1 and D2) that can be resolved by reverse-phase HPLC. A major in vivo pathway for mRNA degradation is initiated by removal of the cap by the pyrophosphatase Dcp1/Dcp2, which cleaves between the alpha- and beta-phosphates. Oligonucleotides capped with m(2) (7,2'-O )Gpp(S)pG (D2) were completely resistant to hydrolysis by recombinant human Dcp2 in vitro, whereas those capped with m(2) (7,2'-O )Gpp(S)pG (D1) and both isomers of m(2) (7,2'-O )Gppp(S)G were partially resistant. Luciferase mRNA capped with m(2) (7,2'-O )Gpp(S)pG (D2) had a t (1/2) of 257 min in cultured HC11 mammary epithelial cells compared with 86 min for m(7)Gp(3)G-capped mRNA. Luciferase mRNAs capped with m(2) (7,2'-O )Gpp(S)pG (D1) and m(2) (7,2'-O )Gpp(S)pG (D2) were translated 2.8-fold and 5.1-fold, respectively, more efficiently in HC11 cells than those capped with m(7)Gp(3)G. The greater yield of protein due to combining higher translational efficiency with longer t (1/2) of mRNA should benefit applications that utilize RNA transfection such as protein production, anti-cancer immunization, and gene therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720878      PMCID: PMC1986804          DOI: 10.1261/rna.701307

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  58 in total

Review 1.  Structures and mechanisms of Nudix hydrolases.

Authors:  A S Mildvan; Z Xia; H F Azurmendi; V Saraswat; P M Legler; M A Massiah; S B Gabelli; M A Bianchet; L-W Kang; L M Amzel
Journal:  Arch Biochem Biophys       Date:  2005-01-01       Impact factor: 4.013

2.  Synthesis and biochemical properties of novel mRNA 5' cap analogs resistant to enzymatic hydrolysis.

Authors:  Marcin Kalek; Jacek Jemielity; Ewa Grudzien; Joanna Zuberek; Elzbieta Bojarska; Lean S Cohen; Janusz Stepinski; Ryszard Stolarski; Richard E Davis; Robert E Rhoads; Edward Darzynkiewicz
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2005       Impact factor: 1.381

Review 3.  Regulation of cap-dependent translation by eIF4E inhibitory proteins.

Authors:  Joel D Richter; Nahum Sonenberg
Journal:  Nature       Date:  2005-02-03       Impact factor: 49.962

4.  Drastic effect of nanoapatite particles on liposome-mediated mRNA delivery to mammalian cells.

Authors:  F T Zohra; E H Chowdhury; M Nagaoka; T Akaike
Journal:  Anal Biochem       Date:  2005-10-01       Impact factor: 3.365

5.  Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination.

Authors:  Jon A Kyte; Gunnar Kvalheim; Steinar Aamdal; Stein Saebøe-Larssen; Gustav Gaudernack
Journal:  Cancer Gene Ther       Date:  2005-06       Impact factor: 5.987

6.  AU binding proteins recruit the exosome to degrade ARE-containing mRNAs.

Authors:  C Y Chen; R Gherzi; S E Ong; E L Chan; R Raijmakers; G J Pruijn; G Stoecklin; C Moroni; M Mann; M Karin
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

Review 7.  RNA transfected dendritic cells as cancer vaccines.

Authors:  D A Mitchell; S K Nair
Journal:  Curr Opin Mol Ther       Date:  2000-04

8.  The DCP2 protein is required for mRNA decapping in Saccharomyces cerevisiae and contains a functional MutT motif.

Authors:  T Dunckley; R Parker
Journal:  EMBO J       Date:  1999-10-01       Impact factor: 11.598

9.  Functional link between the mammalian exosome and mRNA decapping.

Authors:  Z Wang; M Kiledjian
Journal:  Cell       Date:  2001-12-14       Impact factor: 41.582

10.  Ge-1 is a central component of the mammalian cytoplasmic mRNA processing body.

Authors:  Jiang Hong Yu; Wei-Hong Yang; Tod Gulick; Kenneth D Bloch; Donald B Bloch
Journal:  RNA       Date:  2005-12       Impact factor: 4.942

View more
  39 in total

1.  Emerging therapeutics targeting mRNA translation.

Authors:  Abba Malina; John R Mills; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

2.  Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes.

Authors:  Joanna Kowalska; Anna Wypijewska del Nogal; Zbigniew M Darzynkiewicz; Janina Buck; Corina Nicola; Andreas N Kuhn; Maciej Lukaszewicz; Joanna Zuberek; Malwina Strenkowska; Marcin Ziemniak; Maciej Maciejczyk; Elzbieta Bojarska; Robert E Rhoads; Edward Darzynkiewicz; Ugur Sahin; Jacek Jemielity
Journal:  Nucleic Acids Res       Date:  2014-08-22       Impact factor: 16.971

Review 3.  Developing mRNA-vaccine technologies.

Authors:  Thomas Schlake; Andreas Thess; Mariola Fotin-Mleczek; Karl-Josef Kallen
Journal:  RNA Biol       Date:  2012-10-12       Impact factor: 4.652

Review 4.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

5.  Translation, stability, and resistance to decapping of mRNAs containing caps substituted in the triphosphate chain with BH3, Se, and NH.

Authors:  Wei Su; Sergey Slepenkov; Ewa Grudzien-Nogalska; Joanna Kowalska; Marta Kulis; Joanna Zuberek; Maciej Lukaszewicz; Edward Darzynkiewicz; Jacek Jemielity; Robert E Rhoads
Journal:  RNA       Date:  2011-03-29       Impact factor: 4.942

6.  Biomaterials for mRNA delivery.

Authors:  Mohammad Ariful Islam; Emma K G Reesor; Yingjie Xu; Harshal R Zope; Bruce R Zetter; Jinjun Shi
Journal:  Biomater Sci       Date:  2015-08-17       Impact factor: 6.843

7.  Efficient preparation and properties of mRNAs containing a fluorescent cap analog: Anthraniloyl-m(7)GpppG.

Authors:  Dilantha Gunawardana; Artem V Domashevskiy; Ken R Gayler; Dixie J Goss
Journal:  Translation (Austin)       Date:  2015-02-02

8.  Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase DcpS.

Authors:  Joanna Kowalska; Magdalena Lewdorowicz; Joanna Zuberek; Ewa Grudzien-Nogalska; Elzbieta Bojarska; Janusz Stepinski; Robert E Rhoads; Edward Darzynkiewicz; Richard E Davis; Jacek Jemielity
Journal:  RNA       Date:  2008-04-22       Impact factor: 4.942

Review 9.  Viral and Synthetic RNA Vector Technologies and Applications.

Authors:  Juliane W Schott; Michael Morgan; Melanie Galla; Axel Schambach
Journal:  Mol Ther       Date:  2016-07-05       Impact factor: 11.454

10.  mRNAs containing the histone 3' stem-loop are degraded primarily by decapping mediated by oligouridylation of the 3' end.

Authors:  Wei Su; Sergey V Slepenkov; Michael K Slevin; Shawn M Lyons; Marcin Ziemniak; Joanna Kowalska; Edward Darzynkiewicz; Jacek Jemielity; William F Marzluff; Robert E Rhoads
Journal:  RNA       Date:  2012-11-27       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.